Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Bullous Pemphigoid in a Patient Treated with Pembrolizumab.

Hara K, Yamasaki K, Yamada S, Yatera K.

Intern Med. 2019 Sep 11. doi: 10.2169/internalmedicine.3264-19. [Epub ahead of print] No abstract available.

2.

Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Literature.

Zumelzu C, Alexandre M, Le Roux C, Weber P, Guyot A, Levy A, Aucouturier F, Mignot-Grootenboer S, Caux F, Maubec E, Prost-Squarcioni C.

Front Med (Lausanne). 2018 Sep 27;5:268. doi: 10.3389/fmed.2018.00268. eCollection 2018.

3.

Bullous Pemphigoid as an Adverse Reaction to Pembrolizumab: Two Case Reports.

Thomsen K, Diernaes J, Øllegaard TH, Spaun E, Vestergaard C.

Case Rep Dermatol. 2018 Jun 5;10(2):154-157. doi: 10.1159/000489661. eCollection 2018 May-Aug.

4.

Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.

Aggarwal P.

Expert Opin Drug Saf. 2019 Jul;18(7):623-633. doi: 10.1080/14740338.2019.1619693. Epub 2019 May 22.

PMID:
31088310
5.

Pembrolizumab-induced bullous pemphigoid.

Sun CW, Grossman SK, Aphale A, Hsu S.

JAAD Case Rep. 2019 Apr 5;5(4):362-364. doi: 10.1016/j.jdcr.2019.02.008. eCollection 2019 Apr. No abstract available.

6.

A Severe, Refractory Case of Mucous Membrane Pemphigoid After Treatment With Pembrolizumab: Brief Communication.

Bezinelli LM, Eduardo FP, Migliorati CA, Ferreira MH, Taranto P, Sales DB, Santi CG, Macarenco RS, Godoy CPV, Corrêa L, Buzaid AC.

J Immunother. 2019 Nov/Dec;42(9):359-362. doi: 10.1097/CJI.0000000000000280.

PMID:
31246641
7.

Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma.

Parakh S, Nguyen R, Opie JM, Andrews MC.

Australas J Dermatol. 2017 Aug;58(3):e109-e112. doi: 10.1111/ajd.12488. Epub 2016 May 11.

PMID:
27170423
8.

Development of bullous pemphigoid during nivolumab therapy.

Damsky W, Kole L, Tomayko MM.

JAAD Case Rep. 2016 Dec 3;2(6):442-444. eCollection 2016 Nov. No abstract available.

9.

Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression.

Rofe O, Bar-Sela G, Keidar Z, Sezin T, Sadik CD, Bergman R.

Clin Exp Dermatol. 2017 Apr;42(3):309-312. doi: 10.1111/ced.13042. Epub 2017 Feb 16.

PMID:
28211077
10.

Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid.

Beck KM, Dong J, Geskin LJ, Beltrani VP, Phelps RG, Carvajal RD, Schwartz G, Saenger YM, Gartrell RD.

J Immunother Cancer. 2016 Apr 19;4:20. doi: 10.1186/s40425-016-0123-3. eCollection 2016.

11.

Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies.

Hwang SJ, Carlos G, Chou S, Wakade D, Carlino MS, Fernandez-Penas P.

Melanoma Res. 2016 Aug;26(4):413-6. doi: 10.1097/CMR.0000000000000260.

PMID:
27031539
12.

A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab.

Carlos G, Anforth R, Chou S, Clements A, Fernandez-Peñas P.

Melanoma Res. 2015 Jun;25(3):265-8. doi: 10.1097/CMR.0000000000000155.

PMID:
25831416
13.

Severe bullous pemphigoid in a metastatic lung cancer patient treated with pembrolizumab.

Adachi E, Honda T, Nonoyama S, Irie H, Yamamura K, Otsuka A, Kabashima K.

J Dermatol. 2019 Jul;46(7):e232-e233. doi: 10.1111/1346-8138.14813. Epub 2019 Feb 13. No abstract available.

PMID:
30758879
14.

A case report of bullous pemphigoid associated with a melanoma and review of the literature.

Amber KT, Panganiban CM, Korta D, Feraudy S, Kelly KM, Grando SA.

Melanoma Res. 2017 Feb;27(1):65-67. doi: 10.1097/CMR.0000000000000307. Review.

15.

Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions.

Jour G, Glitza IC, Ellis RM, Torres-Cabala CA, Tetzlaff MT, Li JY, Nagarajan P, Huen A, Aung PP, Ivan D, Drucker CR, Prieto VG, Rapini RP, Patel A, Curry JL.

J Cutan Pathol. 2016 Aug;43(8):688-96. doi: 10.1111/cup.12717. Epub 2016 May 8.

PMID:
27086658
16.

Direct immunofluorescence microscopy of 1 mol/L sodium chloride-treated patient skin.

Domloge-Hultsch N, Bisalbutra P, Gammon WR, Yancey KB.

J Am Acad Dermatol. 1991 Jun;24(6 Pt 1):946-51.

PMID:
1869682
17.

Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.

Siegel J, Totonchy M, Damsky W, Berk-Krauss J, Castiglione F Jr, Sznol M, Petrylak DP, Fischbach N, Goldberg SB, Decker RH, Stamatouli AM, Hafez N, Glusac EJ, Tomayko MM, Leventhal JS.

J Am Acad Dermatol. 2018 Dec;79(6):1081-1088. doi: 10.1016/j.jaad.2018.07.008. Epub 2018 Jul 17.

PMID:
30025829
18.

The incidence of internal malignancies in pemphigus and bullous pemphigoid in Japan.

Ogawa H, Sakuma M, Morioka S, Kitamura K, Sasai Y, Imamura S, Inaba Y.

J Dermatol Sci. 1995 Mar;9(2):136-41.

PMID:
7772576
19.
20.

A case of paraneoplastic bullous pemphigoid in association with squamous cell carcinoma of lung.

Das A, Das S, Das SK, Basuthakur S.

J Postgrad Med. 2015 Jul-Sep;61(3):197-9. doi: 10.4103/0022-3859.150906.

Supplemental Content

Support Center